Oncolytics Biotech (TSE:ONC) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech is advancing toward FDA accelerated approval with promising trial results for their breast and pancreatic cancer treatments, particularly highlighting the success of their pelareorep + paclitaxel therapy in the BRACELET-1 trial. The company is also preparing for significant clinical milestones in 2025, including a study that could cement pelareorep as a key therapeutic option for breast cancer patients resistant to current treatments.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.